Introduction
- There are greater than 350,000 out-of-hospital cardiac arrests annually, and nearly 90% of them are
- The effects of epinephrine on animal hemodynamics have been studied since the late 1800s.
- While the first advanced cardiac life support (ACLS) guidelines were first published in 1974, the role
fatal.
of epinephrine remains controversial.
Epinephrine [Adrenalin®]
Dose
Cardiac arrest: 1 mg IV/IO every 3 to 5 minutes
Mechanism of Action
Receptor Activity
Pharmacological Action
Effect
α agonist
Peripheral
vasoconstriction
increased myocardial and cerebral blood
flow
β agonist
increased heart rate and
contractility
increased myocardial oxygen demand
Indications
Asystole/pulseless electrical activity (PEA)
Pulseless ventricular tachycardia/fibrillation
Clinical Detail
Clinical Detail
Mechanism of Action
| Receptor Activity | Pharmacological Action | Effect |
|---|---|---|
| α agonist | Peripheral vasoconstriction | ↑ myocardial and cerebral blood flow |
| β agonist | ↑ heart rate and contractility | ↑ myocardial oxygen demand |
Drug Profile
| Parameter | Detail |
|---|---|
| Indications | Asystole/pulseless electrical activity (PEA); pulseless ventricular tachycardia/fibrillation |
| Onset | Immediate |
| Distribution | 1-2 minutes to reach central circulation during CPR |
| Metabolism | Rapid hepatic degradation |
| Elimination | Urine (inactive metabolites) |
| Half-life | <5 minutes |
| Adverse Effects | Tachyarrhythmias, myocardial ischemia, may decrease cerebral perfusion, mesenteric ischemia, extravasation leading to necrosis, lactic acidosis |
| Dosage Forms | Vial: 1 mg/mL (1 mL & 30 mL); pre-filled syringe: 1 mg/10 mL (10 mL) |
| Compatibility | Compatible with: NS, D5W, and LR. Incompatible with sodium bicarbonate |
Evidence
Evidence
| Author (Year) | Study Design / Patient Population | Intervention | Results |
|---|---|---|---|
| Pearson, 1963 | Animal study (n=80); asphyxiated dogs with asystole and ventricular fibrillation | Epinephrine 1 mg; positive-pressure breathing; chest compressions; defibrillation | ↑ ROSC in dogs that received epinephrine 5 min and 10 min after asystole. ↑ ROSC in dogs that received epinephrine 1 min after ventricular fibrillation. Ventricular fibrillation occurred only in the epinephrine group |
| Stiell, 1992 | RCT (650); out-of-hospital cardiac arrest | Epinephrine 7 mg every 5 min vs. epinephrine 1 mg every 5 min | No difference in survival to hospital admission or discharge and neurologic outcomes between low- and high-dose epinephrine |
| Brown, 1992 | RCT (n=1280); out-of-hospital cardiac arrest | Epinephrine 0.2 mg/kg vs. epinephrine 0.02 mg/kg | No difference in ROSC, survival to hospital admission and discharge, or neurological outcomes between low- and high-dose epinephrine |
| Choux, 1995 | RCT (n=536); out-of-hospital cardiac arrest | Epinephrine 5 mg every 5 min vs. epinephrine 1 mg every 5 min | No difference in ROSC at any time, admission to hospital, or neurological outcomes between low- and high-dose epinephrine |
| Sherman, 1997 | RCT (n=140); out-of-hospital cardiac arrest | Epinephrine 0.1 mg/kg vs. epinephrine 0.01 mg/kg | No difference in rhythm improvement, ROSC, neurologic outcomes, or discharge from hospital between low- and high-dose epinephrine |
| Gueugniaud, 1998 | RCT (n=3327); out-of-hospital cardiac arrest | Epinephrine 5 mg every 3 min vs. epinephrine 1 mg every 3 min | ↑ ROSC in high-dose epinephrine group. No difference in admission to hospital, 24-hour survival, discharge from hospital, or neurological outcomes between low- and high-dose epinephrine |
| Fisk, 2018 | Pre-post study (n=2255); out-of-hospital cardiac arrest | Epinephrine 1 mg at 4 min, then 1 mg every 8 min (2 min for non-shockable rhythms) vs. epinephrine 0.5 mg at 4 min and 8 min, then 0.5 mg every 8 min (2 min for non-shockable rhythms) | No difference in any ROSC, sustained ROSC, survival to discharge, or favorable neurological outcomes between low- and high-dose epinephrine |
| Stiell, 2004 (OPALS) | Pre-post study (n=5638); out-of-hospital cardiac arrest | Rapid defibrillation ACLS (endotracheal intubation & IV medications) | 98.5% of ACLS group received epinephrine. ↑ ROSC and survival to hospital admission in group receiving epinephrine. No difference in survival to hospital discharge and neurological outcomes |
| Olasveengen, 2009 | RCT (n=851); out-of-hospital cardiac arrest | ACLS with IV medications vs. ACLS without IV medications | 79% of IV medication group received epinephrine. ↑ ROSC at any time and survival to hospital admission in group receiving epinephrine. No difference in survival to hospital discharge and neurological outcomes |
| Jacobs, 2011 | RCT (n=534); out-of-hospital cardiac arrest | Epinephrine vs. placebo | ↑ ROSC and survival to hospital admission in group receiving epinephrine. No difference in survival to hospital discharge or neurological outcomes |
| Hagihara, 2012 | Observational study (n=417,188); out-of-hospital cardiac arrest | Epinephrine vs. no epinephrine | ↑ ROSC in group receiving epinephrine. ↓ 1-month survival and neurological outcomes in epinephrine group |
| Perkins, 2018 (PARAMEDIC-2) | RCT (n=8007); out-of-hospital cardiac arrest | Epinephrine 1 mg every 3-5 min vs. placebo | ↑ ROSC, survival to hospital admission, and 30-day survival in epinephrine group. No difference in favorable neurologic outcome at hospital discharge. ↑ severe neurologic impairment in group receiving epinephrine |
Conclusions
- The dose of epinephrine is based on animal studies from the 1960s, in which epinephrine was
- There have been no differences found between standard and high-dose epinephrine.
- Epinephrine may lead to increased ROSC and survival to hospital admission but has not been found
- Bottom Line: Quality chest compressions and early defibrillation continue to be the standard
administered immediately after the induction of cardiac arrest.
to consistently improve long-term outcomes.
of care in ACLS and should not be delayed for administration of epinephrine.
References
Attaran RR, Ewy GA. Epinephrine in resuscitation: curse or cure? Future Cardiology. 2010;6(4).
Callaway C. Epinephrine for cardiac arrest. Current Opinion in Cardiology. 2013;28(1):36-42.
Epinephrine [package insert] Lake Forest, IL: Hospira, Inc.; 2019.
Pearson JW, Redding JS. Epinephrine in cardiac resuscitation. Am Heart J. 1963;66:210-214.
Stiell IG, Hebert PC, Weitzman BN, et al. High-dose epinephrine in adult cardiac arrest. N Engl J Med.
1992;327(15):1045-1050. Choux C, Gueugniaud PY, Barbieux A, et al. Standard doses versus repeated high doses of
epinephrine in cardiac arrest outside the hospital. Resuscitation. 1995;29(1):3-9.
Sherman BW, Munger MA, Foulke GE, Rutherford WF, Panacek EA. High-dose versus standard-dose epinephrine
treatment of cardiac arrest after failure of standard therapy. Pharmacotherapy. 1997;17(2):242-247.
Gueugniaud PY, Mols P, Goldstein P, et al. A comparison of repeated high doses and repeated standard doses of
epinephrine for cardiac arrest outside the hospital. European Epinephrine Study Group. N Engl J Med.
1998;339(22):1595-1601.
Fisk CA, Olsufka M, Yin L, et al. Lower-dose epinephrine administration and out-of-hospital cardiac arrest outcomes.
Resuscitation. 2018;124:43-48.
Stiell IG, Wells GA, Field B, et al. Advanced cardiac life support in out-of-hospital cardiac arrest. N Engl J Med.
2004;351(7):647-656.
Olasveengen TM, Sunde K, Brunborg C, Thowsen J, Steen PA, Wik L. Intravenous drug administration during out-of-
hospital cardiac arrest: a randomized trial. JAMA. 2009;302(20):2222-2229.
Jacobs IG, Finn JC, Jelinek GA, Oxer HF, Thompson PL. Effect of adrenaline on survival in out-of-hospital cardiac
arrest: A randomised double-blind placebo-controlled trial. Resuscitation. 2011;82(9):1138-1143.
Hagihara A, Hasegawa M, Abe T, Nagata T, Wakata Y, Miyazaki S. Prehospital epinephrine use and survival among
patients with out-of-hospital cardiac arrest. JAMA. 2012;307(11):1161-1168.
Perkins GD, Ji C, Deakin CD, et al. A Randomized Trial of Epinephrine in Out-of-Hospital Cardiac Arrest. N Engl J Med.
2018;379(8):711-721.
A short weekly clinical Pearl for acute care pharmacists.
Get the Friday Pearl email
Get a short weekly clinical Pearl for acute care pharmacists. No spam.
Free forever. Unsubscribe anytime. No spam.